Related Experiment Video
Updated: Mar 2, 2026

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome
Published on: June 15, 2016
MicroRNA-1299 is a negative regulator of STAT3 in colon cancer
Yong Wang1, Zhi Lu2, Ningning Wang3
1The 4th Department of Orthopedic Surgery, Central Hospital Affiliated to Shenyang Medical College, Shenyang, Liaoning, P.R. China.
Abstract:
Signal transducers and activators of transcription (STAT) is a family of transcription factors which regulate cell proliferation, differentiation, apoptosis, metastasis, immune and inflammatory responses, and angiogenesis. STAT3 is a latent cytoplasmic transcription factor that belongs to STATs. STAT3 has been reported be regulates genes involved with cellular growth, proliferation and metastasis. Worldwide, colon cancer is one of the leading causes of cancer-related deaths. Cumulative evidence has established that STAT3 is essential for colon cancer progression to advanced malignancy. In our study, we showed that microRNA-1299 (miR-1299) was closely related to the TNM stage of colon cancer, and that the expression of miR-1299 was negatively correlated with the expression of STAT3 in colon cancer which means that miR-1299 can be a negative regulator of STAT3 in colon cancer. A total of 60 cases of different grades of colon samples were used to detect the expression of miR-1299. Results showed that miR-1299 was significantly lower in high-grade colons both in mRNA and protein levels. Furthermore, Overall survival (OS) in patients with low miR-1299 is shorter than 25.6 months, as compared with an OS of 28.4 months in patients with high level of miR-1299. We also confirmed that the overexpression of miR-1299 can not only downregulate the STAT3 pathway, but also inhibited colon cancer cell growth. Our findings could provide new insights into the molecular therapeutic of colon cancer.
Insights
MicroRNA-1299 (miR-1299) is significantly lower in high-grade colon cancer and negatively regulates STAT3. Overexpressing miR-1299 inhibits colon cancer growth, offering potential therapeutic insights.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- Signal transducers and activators of transcription (STAT) proteins, particularly STAT3, are crucial in regulating cellular processes and are implicated in colon cancer progression.
- Colon cancer remains a leading cause of cancer-related mortality worldwide, highlighting the need for novel therapeutic targets.
- STAT3 plays a critical role in promoting colon cancer cell growth, proliferation, and metastasis.
Purpose of the Study:
- To investigate the relationship between microRNA-1299 (miR-1299) and STAT3 in colon cancer.
- To determine the clinical significance of miR-1299 expression in relation to colon cancer stage and patient survival.
- To evaluate the therapeutic potential of miR-1299 in inhibiting colon cancer progression.
Main Methods:
- Analysis of miR-1299 expression in 60 colon cancer samples of varying grades.
- Correlation analysis between miR-1299 and STAT3 expression levels (mRNA and protein).
- Assessment of overall survival (OS) in patients with different levels of miR-1299 expression.
- Experimental validation of miR-1299's effect on STAT3 pathway and colon cancer cell growth through overexpression studies.
Main Results:
- miR-1299 expression was significantly lower in high-grade colon cancer tissues compared to lower grades.
- A negative correlation was observed between miR-1299 and STAT3 expression, indicating miR-1299 acts as a negative regulator of STAT3.
- Patients with low miR-1299 levels exhibited shorter overall survival (25.6 months) than those with high miR-1299 levels (28.4 months).
- Overexpression of miR-1299 successfully downregulated the STAT3 pathway and inhibited colon cancer cell proliferation.
Conclusions:
- miR-1299 is a potential tumor suppressor microRNA in colon cancer, inversely correlated with STAT3.
- Reduced miR-1299 expression is associated with advanced TNM stage and poorer prognosis in colon cancer patients.
- miR-1299 holds promise as a novel molecular therapeutic agent for colon cancer treatment by targeting the STAT3 pathway.
Related Concept Videos
MicroRNAs
MicroRNAs
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Negative Regulator Molecules
PI3K/mTOR/AKT Signaling Pathway
Abnormal Proliferation

